Guggenheim Begins Coverage on Generate Biomedicines (NASDAQ:GENB)

Guggenheim started coverage on shares of Generate Biomedicines (NASDAQ:GENB) in a research report issued on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $30.00 price target on the stock. Guggenheim’s price objective would suggest a potential upside of 153.59% from the company’s previous close.

A number of other research analysts have also recently weighed in on GENB. Cantor Fitzgerald began coverage on shares of Generate Biomedicines in a research report on Tuesday. They set an “overweight” rating on the stock. Wall Street Zen upgraded shares of Generate Biomedicines to a “hold” rating in a report on Saturday, March 14th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $25.00.

Generate Biomedicines Trading Down 1.7%

NASDAQ:GENB opened at $11.83 on Tuesday. Generate Biomedicines has a fifty-two week low of $11.00 and a fifty-two week high of $15.32.

Key Stories Impacting Generate Biomedicines

Here are the key news stories impacting Generate Biomedicines this week:

• Positive Sentiment: Piper Sandler initiated coverage with an “overweight” rating and a $24.00 price target (about 102.9% upside vs. the current $11.83). Article Title Zacks Article
• Positive Sentiment: Morgan Stanley started coverage with an “overweight” and a $20.00 price target (≈69% upside). Article Title TickerReport
• Positive Sentiment: Goldman Sachs initiated with a “buy” and $26.00 target (≈120% upside), another strong institutional vote of confidence. Article Title Zacks Article
• Positive Sentiment: Cantor Fitzgerald added coverage with an “overweight” view. Article Title Zacks Article
• Positive Sentiment: Guggenheim launched coverage with a “buy” and a $30.00 target (≈154% upside), the most aggressive target of the group. Article Title Zacks Article
• Neutral Sentiment: Short-interest reports published today are internally inconsistent (showing 0 shares and NaN days-to-cover), so there is no reliable evidence of significant short pressure based on the released data.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.